James D. Doecke
YOU?
Author Swipe
View article: Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer’s disease
Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer’s disease Open
View article: Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease
Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease Open
INTRODUCTION Plasma phospho‐tau217 (p‐tau217) has been shown to demonstrate equal performance to cerebrospinal fluid (CSF) to predict amyloid beta (Aβ) positivity. Although such high‐performing plasma tests provide confirmatory information…
View article: Combining Lumipulse p‐tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease‐modifying therapy
Combining Lumipulse p‐tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease‐modifying therapy Open
INTRODUCTION For a blood‐based biomarker to be considered a confirmatory test for the detection of abnormal amyloid beta (Aβ) levels, the sensitivity and specificity must be equivalent to that of current cerebrospinal fluid tests. METHODS …
View article: Development and validation of a model to predict the progression of Alzheimer’s disease
Development and validation of a model to predict the progression of Alzheimer’s disease Open
Background Cognition monitoring is crucial for care planning in people with mild cognitive impairment (MCI) and Alzheimer’s dementia (AD). Objective To develop a machine learning model to assist cognition monitoring. Design Florey Fusion M…
View article: Longitudinal associations between self‐reported exercise levels and cognition in ADAD
Longitudinal associations between self‐reported exercise levels and cognition in ADAD Open
INTRODUCTION This study examined longitudinal associations between self‐reported exercise and cognition, with moderation by sex, in individuals with autosomal dominant Alzheimer's disease (ADAD) mutations. We also examined whether changes …
View article: Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study
Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study Open
INTRODUCTION Plasma phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we asse…
View article: Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias
Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias Open
Plasma biomarkers are emerging as noninvasive tools to detect neurodegenerative diseases and monitor treatments in clinical trials. The bPRIDE study investigates blood-based biomarkers to improve the differential diagnosis and molecular st…
View article: Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials Open
Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer’s disease (AD), but their relative performance in predicting future cognitive decline among cognitively unimpaired (CU) individuals is…
View article: Alzheimer’s disease biological PET staging using plasma p217+tau
Alzheimer’s disease biological PET staging using plasma p217+tau Open
View article: Plasma proteomics for cognitive decline and dementia—A Southeast Asian cohort study
Plasma proteomics for cognitive decline and dementia—A Southeast Asian cohort study Open
INTRODUCTION The prognostic utility of plasma proteomics for cognitive decline and dementia in a Southeast Asian population characterized by high cerebrovascular disease (CeVD) burden is underexplored. METHODS We examined this in a Singapo…
View article: Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment Open
View article: Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia
Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia Open
Importance The ability to predict the onset of mild cognitive impairment (MCI) and Alzheimer dementia (AD) could allow older adults and clinicians to make informed decisions about dementia care. Objective To assess whether the age at onset…
View article: Validation of the Alzheimer’s disease-Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire using weighed food records and biomarkers: the Method of Triads model
Validation of the Alzheimer’s disease-Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire using weighed food records and biomarkers: the Method of Triads model Open
The objective was to apply the triangular approach, the Method of Triads, to determine the validity of the Alzheimer’s disease-Commonwealth Scientific and Industrial Research Organisation food frequency questionnaires (FFQ) in 98 cognitive…
View article: Comparing plasma Aβ42/40 and pTau217 to predict Amyloid‐β status across the Alzheimer’s disease continuum
Comparing plasma Aβ42/40 and pTau217 to predict Amyloid‐β status across the Alzheimer’s disease continuum Open
Background Recent advances in immunoassays have enabled sensitive detection of Aβ42/40 and pTau217 in plasma, components of Alzheimer’s disease (AD) neuropathological markers. Further characterization of increased diagnostic accuracy with …
View article: Plasma phospho‐tau 217 rises with and not before early tau aggregation measured by MK6240 PET
Plasma phospho‐tau 217 rises with and not before early tau aggregation measured by MK6240 PET Open
Background Rise in plasma phospho‐tau (pTau) is hypothesized to reflect a physiological response to brain Aβ plaques, preceding the formation of neurofibrillary tangles (NFT). An alternate explanation is poor sensitivity of tau PET for det…
View article: Polygenic scores for Alzheimer’s disease risk and resilience predict age at onset of amyloid‐β
Polygenic scores for Alzheimer’s disease risk and resilience predict age at onset of amyloid‐β Open
Background Genome‐wide association studies (GWAS) have identified numerous genetic variants associated with Alzheimer’s disease (AD) risk, but genetic variation in the onset and progression of AD pathology is less understood. Accumulation …
View article: Plasma metabolites associated with plasma P‐tau181 in preclinical Alzheimer's disease
Plasma metabolites associated with plasma P‐tau181 in preclinical Alzheimer's disease Open
Background Alzheimer's disease (AD) pathogenesis is not restricted to amyloid‐beta, Aβ, and tau pathologies but involves dysregulation in diverse cellular and molecular processes. Numerous metabolomic studies revealed plasma metabolite alt…
View article: Harmonization of data from neuropsychological tests used in different prospective studies‐ Descending a Tower of Babel
Harmonization of data from neuropsychological tests used in different prospective studies‐ Descending a Tower of Babel Open
Background Cognitive dysfunction is central to clinicopathological models of Alzheimer’s disease (AD). While AD prospective studies assess similar cognitive domains, the neuropsychological tests used vary between studies, limiting potentia…
View article: Cross‐cohort epigenome‐wide association study in Alzheimer’s disease risk and related traits
Cross‐cohort epigenome‐wide association study in Alzheimer’s disease risk and related traits Open
Background Epigenome‐wide association studies (EWAS) have identified multiple loci that are differentially methylated in Alzheimer’s disease (AD). However, for complex diseases such as AD, single methylation sites associated with disease a…
View article: Cross‐cohort epigenome‐wide association study in Alzheimer's disease risk and related traits
Cross‐cohort epigenome‐wide association study in Alzheimer's disease risk and related traits Open
Background Epigenome‐wide association studies (EWAS) have identified multiple loci that are differentially methylated in Alzheimer’s disease (AD). However, for complex diseases such as AD, single methylation sites associated with disease a…
View article: Data‐driven Cognitive Composites and <i>APOE</i> ε4 Carriage Predict Progression to Mild Cognitive Impairment in Cognitively Unimpaired Older Adults
Data‐driven Cognitive Composites and <i>APOE</i> ε4 Carriage Predict Progression to Mild Cognitive Impairment in Cognitively Unimpaired Older Adults Open
Background In cognitively unimpaired (CU) individuals, the PACC is widely used as a cognitive outcome measure and endpoint in observational studies and clinical trials. However, it has drawn criticism for being heavily weighted towards mem…
View article: Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive decline
Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive decline Open
Background The success of therapeutic options for treatment of Alzheimer’s disease (AD) and the growing emphasis for such treatment to commence in the pre‐clinical phase makes it necessary to have robust empirical models of clinical diseas…
View article: OML‐Combine: Online Machine Learning tool for Combining datasets to increase power and facilitate multi‐centre collaboration on Alzheimer's disease studies
OML‐Combine: Online Machine Learning tool for Combining datasets to increase power and facilitate multi‐centre collaboration on Alzheimer's disease studies Open
Background Diagnostic and prognostic decisions about Alzheimer’s disease (AD) are more accurate when based on large data sets. We developed and validated a machine learning (ML) data harmonization tool for aggregation of prospective data f…
View article: Longitudinal associations between self‐reported exercise levels and Alzheimer’s related biomarkers in Autosomal Dominant Alzheimer’s Disease
Longitudinal associations between self‐reported exercise levels and Alzheimer’s related biomarkers in Autosomal Dominant Alzheimer’s Disease Open
Background Accumulating evidence indicates exercise may delay or prevent the onset of Alzheimer’s disease (AD). To our knowledge, no study has investigated the longitudinal impact of exercise on AD‐related biomarkers in individuals with Au…
View article: Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive decline
Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive decline Open
Background The success of therapeutic options for treatment of Alzheimer’s disease (AD) and the growing emphasis for such treatment to commence in the pre‐clinical phase makes it necessary to have robust empirical models of clinical diseas…
View article: Plasma p217+tau accurately discriminates Intermediate or Advanced Alzheimer's Disease biological PET stages
Plasma p217+tau accurately discriminates Intermediate or Advanced Alzheimer's Disease biological PET stages Open
Background Plasma phospho‐tau biomarkers, such as p217+tau, excel at identifying Alzheimer’s Disease (AD) neuropathology. However, questions remain regarding their capacity to inform AD biological PET stages at group level and maintain the…
View article: Plasma phospho‐tau 217 rises with and not before early tau aggregation measured by MK6240 PET
Plasma phospho‐tau 217 rises with and not before early tau aggregation measured by MK6240 PET Open
Background Rise in plasma phospho‐tau (pTau) is hypothesized to reflect a physiological response to brain Aß plaques, preceding the formation of neurofibrillary tangles (NFT). An alternate explanation is poor sensitivity of tau PET for det…
View article: Circulating medium‐ and long‐chain acylcarnitines are associated with plasma P‐tau181 in cognitively normal older adults
Circulating medium‐ and long‐chain acylcarnitines are associated with plasma P‐tau181 in cognitively normal older adults Open
Alzheimer's disease (AD) pathogenesis involves dysregulation in diverse biochemical processes. Nevertheless, plasma tau phosphorylated at threonine 181 (P‐tau181), a recognised AD biomarker, has been described to reflect early‐stage cortic…
View article: Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform
Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform Open
View article: Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer's disease
Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer's disease Open
INTRODUCTION We investigated longitudinal associations between self‐reported exercise and Alzheimer's disease (AD)‐related biomarkers in individuals with autosomal dominant AD (ADAD) mutations. METHODS Participants were 308 ADAD mutation c…